CoChat

Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects

Open access
Nguyen, Phuong A., Born, David A., Deaton, Aimee M., Nioi, Paul, Ward, Lucas D. · 2019 · Nature Communications

Published version of a preprint

Cited by 101

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Only a small fraction of early drug programs progress to the market, due to safety and efficacy failures, despite extensive efforts to predict safety. Characterizing the effect of natural variation in the genes encoding drug targets should present a powerful approach to predict side effects arising from drugging particular proteins. In this retrospective analysis, we report a correlation between the organ systems affected by genetic variation in drug targets and the organ systems in which side effects are observed. Across 1819 drugs and 21 phenotype categories analyzed, drug side effects are more likely to occur in organ systems where there is genetic evidence of a link between the drug target and a phenotype involving that organ system, compared to when there is no such genetic evidence (30.0 vs 19.2%; OR = 1.80). This result suggests that human genetic data should be used to predict safety issues associated with drug targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09407-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 47

  1. Plenge, R. M. Disciplined approach to drug discovery and early development. Sci. Transl. Med 8, 349ps315 (2016). · DOI · Paper page
  2. Knowles, J. & Gromo, G. A guide to drug discovery: target selection in drug discovery. Nat. Rev. Drug. Discov. 2, 63–69 (2003). · DOI · Paper page
  3. Lindsay, M. A. Target discovery. Nat. Rev. Drug. Discov. 2, 831–838 (2003). · DOI · Paper page
  4. Ma, P. & Zemmel, R. Value of novelty? Nat. Rev. Drug. Discov. 1, 571–572 (2002). · DOI · Paper page
  5. Duran-Frigola, M. & Aloy, P. Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem. Biol. 20, 594–603 (2013). · DOI
  6. Duran-Frigola, M., Rossell, D. & Aloy, P. A chemo-centric view of human health and disease. Nat. Commun. 5, 5676 (2014). · DOI
  7. Juan-Blanco, T., Duran-Frigola, M. & Aloy, P. IntSide: a web server for the chemical and biological examination of drug side effects. Bioinformatics 31, 612–613 (2015). · DOI
  8. Garcia-Serna, R. & Mestres, J. Anticipating drug side effects by comparative pharmacology. Expert. Opin. Drug. Metab. Toxicol. 6, 1253–1263 (2010). · DOI
  9. LaBute, M. X. et al. Adverse drug reaction prediction using scores produced by large-scale drug-protein target docking on high-performance computing machines. PLoS. ONE 9, e106298 (2014). · DOI
  10. Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361–367 (2012). · DOI · Paper page
  11. Scheiber, J. et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 49, 308–317 (2009). · DOI · Paper page
  12. Leeson, P. Drug discovery: chemical beauty contest. Nature 481, 455–456 (2012). · DOI · Paper page
  13. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001). · DOI · Paper page
  14. Alfirevic, A. & Pirmohamed, M. Genomics of adverse drug reactions. Trends Pharmacol. Sci. 38, 100–109 (2017). · DOI
  15. Hauser, A. S. et al. Pharmacogenomics of GPCR drug targets. Cell 172, 41–54 e19 (2018). · DOI · Paper page
  16. Ferrero, E., Dunham, I. & Sanseau, P. In silico prediction of novel therapeutic targets using gene-disease association data. J. Transl. Med. 15, 182 (2017). · DOI · Paper page
  17. Kamb, A., Harper, S. & Stefansson, K. Human genetics as a foundation for innovative drug development. Nat. Biotechnol. 31, 975–978 (2013). · DOI
  18. Dorato, M. A. & Engelhardt, J. A. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul. Toxicol. Pharmacol. 42, 265–274 (2005). · DOI · Paper page
  19. Knox, C. et al. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res. 39, D1035–D1041 (2011). · DOI · Paper page
  20. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014). · DOI · Paper page
  21. Wishart, D. S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901–D906 (2008). · DOI · Paper page
  22. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug. Discov. 16, 19–34 (2017). · DOI · Paper page
  23. Shen, J., Song, K., Slater, A., Ferrero, E. & Nelson, M. R. STOPGAP: a database for systematic target opportunity assessment by genetic association predictions. Bioinformatics, https://doi.org/10.1093/bioinformatics/btx274 (2017). · DOI
  24. Begum, T., Ghosh, T. C. & Basak, S. Systematic analyses and prediction of human drug side effect associated proteins from the perspective of protein evolution. Genome Biol. Evol. 9, 337–350 (2017). · DOI
  25. Diogo, D. et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat. Commun. 9, 4285 (2018). · DOI · Paper page
  26. Prasad, N. et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? Nephrology 19, 244–250 (2014). · DOI
  27. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723–735 (2005). · DOI · Paper page
  28. Plagnol, V. et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet. 7, e1002216 (2011). · DOI · Paper page
  29. Caudy, A. A., Reddy, S. T., Chatila, T., Atkinson, J. P. & Verbsky, J. W. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119, 482–487 (2007). · DOI · Paper page
  30. Madhani, P., Hughes, J. & Ballard, C. G. Cholinesterase inhibitors and the heart in old age. Adv. Psychiatr. Treat. 10, 399–399 (2004). · doi:10.1192/apt.10.5.399
  31. ADRAC. Cholinesterase inhibitors and cardiac arrhythmias. Australian Adverse Drug Reactions Bulletin 23, 19 (2004).
  32. den Hoed, M. et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat. Genet. 45, 621–631 (2013). · DOI · Paper page
  33. Eppinga, R. N. et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat. Genet. 48, 1557–1563 (2016). · DOI
  34. Masuda, Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer’s disease—from basic research to bedside. Curr. Alzheimer Res. 1, 315–321 (2004). · doi:10.2174/1567205043332009
  35. Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A. & Hughes, B. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 64, 2387–2397 (2012). · DOI · Paper page
  36. Arnold, L. M., Chatamra, K., Hirsch, I. & Stoker, M. Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 32, 1618–1632 (2010). · DOI
  37. Denolle, T., Pellizzoni, C., Jannuzzo, M. G. & Poggesi, I. Hemodynamic effects of reboxetine in healthy male volunteers. Clin. Pharmacol. Ther. 66, 282–287 (1999). · DOI
  38. Paczkowski, F. A., Bonisch, H. & Bryan-Lluka, L. J. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter. Pharmacogenetics 12, 165–173 (2002). · DOI
  39. Mullard, A. Calls grow to tap the gold mine of human genetic knockouts. Nat. Rev. Drug. Discov. 16, 515–518 (2017). · DOI
  40. Szklarczyk, D. et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 44, D380–D384 (2016). · DOI · Paper page
  41. Tasneem, A. et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS. ONE 7, e33677 (2012). · DOI · Paper page
  42. Kohler, S. et al. The human phenotype ontology in 2017. Nucleic Acids Res. 45, D865–D876 (2017). · DOI · Paper page
  43. McInnes, B. T., Pedersen, T. & Pakhomov, S. V. UMLS-Interface and UMLS-Similarity: open source software for measuring paths and semantic similarity. Amia. Annu. Symp. Proc. 2009, 431–435 (2009).
  44. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015). · DOI · Paper page
  45. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). · DOI · Paper page
  46. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010). · DOI · Paper page
  47. Tibshirani, R. et al. Strong rules for discarding predictors in lasso-type problems. J. R. Stat. Soc. Ser. B Stat. Methodol. 74, 245–266 (2012). · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D.
Venue
Nature Communications
Published
2019-04-05
Volume
10
Issue
1
Pages
1579-1579
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2950070451
Cited by
101
References
21
FWCI
9.66
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. https://app.cochat.ai/papers/10.1038/s41467-019-09407-3
The paper
Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D. (2019). Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nature Communications. https://doi.org/10.1038/s41467-019-09407-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.